According to a media release from Adamis Pharmaceuticals, the company has started to enroll patients into a Phase I/IIa clinical trial of APC-100 in men with castration-resistant prostate cancer (CRPC).
APC-100 appears to affect the progression of prostate cancer through multiple mechanisms of action (at least in animal models and in vitro). Whether it will have the same level of activity in men with CRPC may take a little while to determine. Limited information about this drug is currently available on the Web. No information about this trial is given on the ClinicalTrials.gov web site. However, this study is being conducted by members of the Prostate Cancer Clinical Trials Consortium, which does give some credibility to the potential of APC-100.
It is not entirely clear at this time whether the trial is limited to men with clear evidence of metastatic disease, but we believe that this is the case based on prior information released by the company.
Filed under: Drugs in development, Management Tagged: | Adamis, APC-100, casrtation-resistant
Search for new and
ongoing trials on the
CTAG PCa web site
